Cargando…
Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management
INTRODUCTION: To compare health services utilization and payments for cancer patients who received an implantable intrathecal drug delivery (IDD) system, consisting of a pump and catheter, vs. conventional medical management (CMM) for the treatment of cancer‐related pain. METHODS: This retrospective...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066649/ https://www.ncbi.nlm.nih.gov/pubmed/26816205 http://dx.doi.org/10.1111/ner.12384 |
_version_ | 1782460522688413696 |
---|---|
author | Stearns, Lisa J. Hinnenthal, Jennifer A. Hammond, Krisstin Berryman, Eric Janjan, Nora A. |
author_facet | Stearns, Lisa J. Hinnenthal, Jennifer A. Hammond, Krisstin Berryman, Eric Janjan, Nora A. |
author_sort | Stearns, Lisa J. |
collection | PubMed |
description | INTRODUCTION: To compare health services utilization and payments for cancer patients who received an implantable intrathecal drug delivery (IDD) system, consisting of a pump and catheter, vs. conventional medical management (CMM) for the treatment of cancer‐related pain. METHODS: This retrospective claims‐data analysis compared health services utilization and payments in a population of patients receiving either IDD or CMM for treatment of cancer pain. Patients were propensity score‐matched 1:1 based on characteristics including, but not limited to, age, gender, cancer type, comorbid conditions, and health care utilization and payments. RESULTS: From a sample of 142 IDD patients and 3188 CMM patients who met all inclusion/exclusion criteria, 73 matched pairs were obtained. In the year following implant, IDD patients had a consistent trend of lower medical utilization, and total payments that were $3195 lower compared to CMM. CONCLUSIONS: Despite the high initial cost of IDD, this analysis suggests that patients with IDD incur lower medical utilization and payments over the first year post‐implant. Further analysis comprised of a larger, longitudinal sample would contribute to health economics and outcomes research, and assist with future practice guideline development. |
format | Online Article Text |
id | pubmed-5066649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-50666492016-11-01 Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management Stearns, Lisa J. Hinnenthal, Jennifer A. Hammond, Krisstin Berryman, Eric Janjan, Nora A. Neuromodulation Intrathecal Drug Delivery Systems INTRODUCTION: To compare health services utilization and payments for cancer patients who received an implantable intrathecal drug delivery (IDD) system, consisting of a pump and catheter, vs. conventional medical management (CMM) for the treatment of cancer‐related pain. METHODS: This retrospective claims‐data analysis compared health services utilization and payments in a population of patients receiving either IDD or CMM for treatment of cancer pain. Patients were propensity score‐matched 1:1 based on characteristics including, but not limited to, age, gender, cancer type, comorbid conditions, and health care utilization and payments. RESULTS: From a sample of 142 IDD patients and 3188 CMM patients who met all inclusion/exclusion criteria, 73 matched pairs were obtained. In the year following implant, IDD patients had a consistent trend of lower medical utilization, and total payments that were $3195 lower compared to CMM. CONCLUSIONS: Despite the high initial cost of IDD, this analysis suggests that patients with IDD incur lower medical utilization and payments over the first year post‐implant. Further analysis comprised of a larger, longitudinal sample would contribute to health economics and outcomes research, and assist with future practice guideline development. John Wiley and Sons Inc. 2016-01-27 2016-02 /pmc/articles/PMC5066649/ /pubmed/26816205 http://dx.doi.org/10.1111/ner.12384 Text en © 2016 The Authors. Neuromodulation: Technology at the Neural Interface published by Wiley Periodicals, Inc. on behalf of International Neuromodulation Society This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Intrathecal Drug Delivery Systems Stearns, Lisa J. Hinnenthal, Jennifer A. Hammond, Krisstin Berryman, Eric Janjan, Nora A. Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management |
title | Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management |
title_full | Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management |
title_fullStr | Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management |
title_full_unstemmed | Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management |
title_short | Health Services Utilization and Payments in Patients With Cancer Pain: A Comparison of Intrathecal Drug Delivery vs. Conventional Medical Management |
title_sort | health services utilization and payments in patients with cancer pain: a comparison of intrathecal drug delivery vs. conventional medical management |
topic | Intrathecal Drug Delivery Systems |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066649/ https://www.ncbi.nlm.nih.gov/pubmed/26816205 http://dx.doi.org/10.1111/ner.12384 |
work_keys_str_mv | AT stearnslisaj healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement AT hinnenthaljennifera healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement AT hammondkrisstin healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement AT berrymaneric healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement AT janjannoraa healthservicesutilizationandpaymentsinpatientswithcancerpainacomparisonofintrathecaldrugdeliveryvsconventionalmedicalmanagement |